India Pharma Outlook Team | Tuesday, 14 July 2026
The Indian Pharma Industry is moving towards a biosimilars manufacturing growth phase. Earlier this year, India was the subject of a global collaboration that reflects growing international trust in its abilities.
OneSource Specialty Pharma has partnered with Germany-based Formycon AG. The deal focuses on manufacturing biosimilars for global markets.
This development reflects India’s cost advantage and technical expertise. It also shows strong global investments in pharma manufacturing.
India is gradually emerging as an attractive destination for biologics manufacturing. This partnership paves the way for future expansion in Indian pharmaceutical exports. It also enhances India's global position in the biosimilars manufacturing value chain.
The new partnership between OneSource Specialty Pharma and Formycon AG marks a key milestone. This cross-border deal strengthens biosimilars manufacturing capabilities in India. OneSource will serve as a strategic manufacturing partner for Formycon. It will provide integrated Drug Substance and Drug Product manufacturing services.
This collaboration highlights India’s role in global pharma supply chains. It also reflects increasing trust from international biotech firms. The deal leverages India’s cost-efficient manufacturing infrastructure. It also benefits from a highly skilled workforce and regulatory expertise.
Such partnerships improve scalability and production efficiency. They help meet rising global demand for biosimilars. The agreement also enhances technology transfer and knowledge sharing. This will improve quality standards and compliance globally.
The partnership strengthens supply chain resilience for biologics manufacturing. It reduces dependency on limited production hubs worldwide. It also ensures faster turnaround times for global markets. Also, logistics efficiency is expected to improve due to India’s expanding export capabilities.
This deal aligns with growing global investments in pharma. It shows how Indian firms attract international collaborations. These developments position India as a reliable biosimilars manufacturing hub.
Also Read: Pharmaceutical 4.0: Redefines Compliance, Automation & AI
Biosimilars are cost-effective alternatives to expensive biologic drugs. They play a key role in improving healthcare access globally. Manufacturing biosimilars requires advanced technology and expertise. India has developed strong capabilities in this segment.
Biosimilars manufacturing offers significant economic benefits. It drives exports and increases foreign exchange earnings. It also creates high-value jobs in research and production. The sector supports innovation and technological advancement.
“This partnership reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics", said Neeraj Sharma, CEO and Managing Director, OneSource Specialty Pharma.
For the market, biosimilars reduce treatment costs significantly. This increases patient access to life-saving therapies. It also expands market size for pharmaceutical companies. Also, lower prices drive higher adoption rates globally.
Similarly, biosimilars also open new revenue streams. Companies can enter regulated markets like Europe and the US, which will in turn improve profitability and global competitiveness.
Supply chains benefit from diversified manufacturing locations as India’s infrastructure supports large-scale biologics production. This ensures consistent supply and reduces shortages.
OneSource Specialty Pharma is an Indian pharmaceutical company focused on advanced drug manufacturing services. It specializes in biologics and offers integrated Drug Substance and Drug Product capabilities.
